Xolair can cost $1,500-$4,000+ per injection. Here's how to save with co-pay programs, patient assistance, biosimilars, and other strategies in 2026.
If you've been prescribed Xolair (Omalizumab) for asthma, chronic hives, nasal polyps, or food allergy, you already know it can be a transformative medication. What you may also know is that it's one of the most expensive prescription drugs many patients will ever encounter.
Without insurance or financial assistance, a single Xolair injection can cost $1,500 to $4,000 or more, depending on the dose. That translates to $30,000 to $50,000+ per year for patients receiving injections every 2 to 4 weeks.
The good news: there are real ways to reduce what you pay. This guide walks through every major option — from manufacturer programs to the biosimilar to patient assistance — so you can stay on treatment without breaking the bank.
Xolair is a biologic medication, and biologics are among the most expensive drug categories. Here's what you're looking at without any coverage or discounts:
Most patients receive either one or two injections per session, every 2 to 4 weeks. That means annual out-of-pocket costs can easily exceed $30,000 to $50,000.
These prices apply whether you get the injection at your doctor's office or through a specialty pharmacy for home self-injection.
If you have commercial (private) health insurance, the Genentech Co-pay Program is the first place to look. This manufacturer-sponsored program can reduce your out-of-pocket cost to as low as $0 per dose.
Key details:
This program alone can save thousands of dollars per year. If you have commercial insurance and aren't already enrolled, this should be your first step.
If you are uninsured or underinsured, the Genentech Patient Foundation may provide Xolair completely free of charge.
Key details:
This program is a lifeline for patients who would otherwise have no way to afford a biologic medication costing tens of thousands of dollars per year.
One of the most significant developments for Xolair affordability in 2026 is the FDA-approved biosimilar Omlyclo (Omalizumab-igec) from Mylan/Viatris.
A biosimilar is the biologic equivalent of a generic drug. It works the same way, has the same safety profile, and meets the same FDA standards. The key advantage: biosimilars are typically priced 15% to 30% lower than the brand-name product.
What this means for you:
Ask your doctor or insurance company whether Omlyclo is available and covered under your plan. For clinical details on the biosimilar, see What Is Xolair?
Prescription discount cards can sometimes help reduce the cost of Xolair, though savings on specialty biologics are typically smaller than for common generics. Still, it's worth checking:
Important note: Discount cards cannot be combined with insurance. They're most useful for uninsured patients who don't qualify for the patient foundation. For Xolair specifically, the manufacturer programs typically provide much greater savings than third-party discount cards.
Beyond Genentech's own foundation, several independent organizations maintain databases of patient assistance programs:
These resources can be especially helpful if you've been turned down by the manufacturer's program or need help navigating the application process.
How your insurance handles Xolair can make a huge difference in your cost. Here are strategies to optimize your coverage:
Xolair may be covered under your medical benefit (Part B if Medicare, or medical if commercial) when administered in a doctor's office, or under your pharmacy benefit when self-injected at home. The copay structure can be very different depending on which benefit applies. Ask your insurance company which benefit covers Xolair for your situation.
If your insurance denies prior authorization for Xolair, you have the right to appeal. Work with your doctor to submit a letter of medical necessity. Many initial denials are overturned on appeal.
If Xolair is placed on a high specialty tier with a large coinsurance percentage, you can request a tier exception. Your doctor provides documentation showing that Xolair is medically necessary and there is no appropriate lower-tier alternative.
Some insurers are placing Omlyclo on a preferred tier with lower copays compared to brand-name Xolair. Switching to the biosimilar may lower your cost even within the same insurance plan.
Xolair is an expensive medication, but very few patients need to pay the full cash price. Between the manufacturer's co-pay program (potentially $0 for commercially insured patients), the patient foundation (free medication for qualifying uninsured patients), and the new biosimilar option, most patients can find a way to make Xolair affordable.
Start by talking to your doctor's office — they deal with Xolair access and cost issues regularly and can guide you to the right programs. And if finding Xolair in stock is also a challenge, use Medfinder to check real-time availability near you.
Related guides:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
